SG11201704651UA - Pyridazinone macrocycles as irak inhibitors and uses thereof - Google Patents
Pyridazinone macrocycles as irak inhibitors and uses thereofInfo
- Publication number
- SG11201704651UA SG11201704651UA SG11201704651UA SG11201704651UA SG11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA
- Authority
- SG
- Singapore
- Prior art keywords
- macrocycles
- pyridazinone
- irak inhibitors
- irak
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562112793P | 2015-02-06 | 2015-02-06 | |
PCT/US2016/016708 WO2016127024A1 (en) | 2015-02-06 | 2016-02-05 | Pyridazinone macrocycles as irak inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704651UA true SG11201704651UA (en) | 2017-07-28 |
Family
ID=55436166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704651UA SG11201704651UA (en) | 2015-02-06 | 2016-02-05 | Pyridazinone macrocycles as irak inhibitors and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US9624246B2 (de) |
EP (1) | EP3253763B1 (de) |
JP (1) | JP6920202B2 (de) |
KR (1) | KR102551597B1 (de) |
CN (1) | CN107428765B (de) |
AU (1) | AU2016215184B2 (de) |
BR (1) | BR112017014970B1 (de) |
CA (1) | CA2970550C (de) |
ES (1) | ES2841452T3 (de) |
HK (1) | HK1246287A1 (de) |
IL (1) | IL253519B (de) |
MX (1) | MX2017009624A (de) |
RU (1) | RU2708066C2 (de) |
SG (1) | SG11201704651UA (de) |
WO (1) | WO2016127024A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017014970B1 (pt) * | 2015-02-06 | 2022-11-16 | Merck Patent Gmbh | Macrociclos de piridazinona como inibidores de irak, seus usos, e composição farmacêutica |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
CN109956957B (zh) * | 2017-12-22 | 2021-11-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
IL277408B1 (en) * | 2018-04-05 | 2024-04-01 | Merck Patent Gmbh | Heteroaryl compounds as IRAK type II inhibitors and their use |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
CN112566697B (zh) | 2018-08-13 | 2024-04-16 | 吉利德科学公司 | 作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物 |
TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
AU2019321267B2 (en) | 2018-08-13 | 2022-07-14 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors |
US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
CN111603471B (zh) * | 2020-06-24 | 2021-07-09 | 山东省科学院生物研究所 | 一种邻二氮杂环化合物在制备抑制tlr4受体的药物中的用途 |
US20230357271A1 (en) * | 2020-09-30 | 2023-11-09 | Asahi Kasei Pharma Corporation | Macrocyclic compound |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
JP2010138073A (ja) * | 2007-03-30 | 2010-06-24 | Taisho Pharmaceutical Co Ltd | ピコリン酸アミド化合物 |
US8703768B2 (en) * | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
EP2903613B1 (de) * | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazolderivate zur verwendung als inhibitoren der irak4-aktivität |
WO2014121931A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
SI2953952T1 (sl) * | 2013-02-07 | 2017-10-30 | Merck Patent Gmbh | Makrociklični piridazinonski derivati |
BR112017014970B1 (pt) * | 2015-02-06 | 2022-11-16 | Merck Patent Gmbh | Macrociclos de piridazinona como inibidores de irak, seus usos, e composição farmacêutica |
-
2016
- 2016-02-05 BR BR112017014970-2A patent/BR112017014970B1/pt active IP Right Grant
- 2016-02-05 AU AU2016215184A patent/AU2016215184B2/en active Active
- 2016-02-05 CA CA2970550A patent/CA2970550C/en active Active
- 2016-02-05 MX MX2017009624A patent/MX2017009624A/es unknown
- 2016-02-05 KR KR1020177020262A patent/KR102551597B1/ko active IP Right Grant
- 2016-02-05 US US15/016,584 patent/US9624246B2/en active Active
- 2016-02-05 WO PCT/US2016/016708 patent/WO2016127024A1/en active Application Filing
- 2016-02-05 ES ES16706471T patent/ES2841452T3/es active Active
- 2016-02-05 JP JP2017539435A patent/JP6920202B2/ja active Active
- 2016-02-05 EP EP16706471.6A patent/EP3253763B1/de active Active
- 2016-02-05 SG SG11201704651UA patent/SG11201704651UA/en unknown
- 2016-02-05 CN CN201680018681.1A patent/CN107428765B/zh active Active
- 2016-02-05 RU RU2017130761A patent/RU2708066C2/ru active
-
2017
- 2017-03-06 US US15/450,463 patent/US10517872B2/en active Active
- 2017-07-17 IL IL253519A patent/IL253519B/en active IP Right Grant
-
2018
- 2018-05-04 HK HK18105786.7A patent/HK1246287A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112017014970B1 (pt) | 2022-11-16 |
KR20170113551A (ko) | 2017-10-12 |
JP6920202B2 (ja) | 2021-08-18 |
US20160229871A1 (en) | 2016-08-11 |
US10517872B2 (en) | 2019-12-31 |
EP3253763B1 (de) | 2020-09-30 |
KR102551597B1 (ko) | 2023-07-05 |
IL253519B (en) | 2021-01-31 |
IL253519A0 (en) | 2017-09-28 |
HK1246287A1 (zh) | 2018-09-07 |
CA2970550A1 (en) | 2016-08-11 |
CN107428765A (zh) | 2017-12-01 |
EP3253763A1 (de) | 2017-12-13 |
NZ732527A (en) | 2022-03-25 |
RU2708066C2 (ru) | 2019-12-04 |
AU2016215184A1 (en) | 2017-06-29 |
AU2016215184B2 (en) | 2020-11-12 |
MX2017009624A (es) | 2017-11-20 |
JP2018505166A (ja) | 2018-02-22 |
US20170173019A1 (en) | 2017-06-22 |
RU2017130761A3 (de) | 2019-07-17 |
US9624246B2 (en) | 2017-04-18 |
WO2016127024A1 (en) | 2016-08-11 |
CA2970550C (en) | 2023-09-19 |
RU2017130761A (ru) | 2019-03-06 |
BR112017014970A2 (pt) | 2018-03-27 |
CN107428765B (zh) | 2020-12-29 |
ES2841452T3 (es) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246287A1 (zh) | 用作irak抑制劑的噠嗪酮類大環化合物及其用途 | |
HK1255102A1 (zh) | 雜環化合物及其應用 | |
HK1256997A1 (zh) | Tyk2抑制劑及其用途 | |
HK1248690A1 (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
ZA201702402B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
ZA201801056B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
EP3134091A4 (de) | Irak-hemmer und verwendungen davon | |
ZA201800975B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
GB201605126D0 (en) | Inhibitors and their uses | |
IL280863A (en) | Ototaxin inhibitors and their uses | |
HK1256417A1 (zh) | 氰基噻吩並三唑並二氮雜環庚三烯及其用途 | |
HK1246780A1 (zh) | 氮雜-吡啶酮化合物及其用途 | |
HK1249108A1 (zh) | Mir-92抑制劑及其用途 | |
HK1250926A1 (zh) | 抑制劑及其應用 | |
HK1247122A1 (zh) | 組合及其用途 | |
IL254241A0 (en) | Etv2 and its uses | |
GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201505975D0 (en) | Inhibitors and their uses |